Thermo Fisher Scientific (TMO) Sets Stage for Q4 Rally with Impressive Q3 Earnings and New 52-Week High

2 hours ago 1

Soumya Eswaran

Mon, March 30, 2026 astatine 8:37 AM CDT 3 min read

Bristol Gate Capital Partners, an concern absorption company, published its Q4 2025 capitalist missive for the “US Equity Strategy”. A transcript of the missive tin beryllium downloaded here. Bristol Gate prioritizes companies with beardown escaped currency flows, disciplined superior allocation, and precocious dividend maturation for superior risk-adjusted returns. These resilient businesses align absorption interests with shareholders done sustainable dividends. Since precocious 2022, the marketplace has shifted towards AI leaders, resulting successful the fund's underperformance owed to constrictive breadth. While the steadfast invests successful information subject and AI, the absorption remains connected precocious dividend maturation companies. Recently, this constrictive absorption was shifting, supported by the outperformance of the S&P US Dividend Growers, S&P 500 Dividend Aristocrats, and S&P 500 Equal Weight. This marketplace breadth expansion, on with the firm’s Data Science team's advancements successful the Distant Future Model, offers a beardown accidental for investors to bargain the strategy and mitigate risks successful the existent concentrated market. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Bristol Gate Capital Partners US Equity Strategy highlighted Thermo Fisher Scientific Inc. (NYSE:TMO) arsenic 1 of its starring contributors. Thermo Fisher Scientific Inc. (NYSE:TMO) is simply a beingness subject and objective probe institution focusing connected providing beingness sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. On March 27, 2026, Thermo Fisher Scientific Inc. (NYSE:TMO) closed astatine $473.36 per share. One-month instrumentality of Thermo Fisher Scientific Inc. (NYSE:TMO) was -6.93%, and its shares mislaid 4.87% implicit the past 52 weeks. Thermo Fisher Scientific Inc. (NYSE:TMO) has a marketplace capitalization of $175.846 billion.

Bristol Gate Capital Partners US Equity Strategy stated the pursuing regarding Thermo Fisher Scientific Inc. (NYSE:TMO) successful its 4th fourth 2025 capitalist letter:

"Thermo Fisher Scientific Inc.'s (NYSE:TMO) instauration for the Q4 rally, hitting a caller 52-week precocious successful precocious December, started with a beardown Q3 net merchandise adjacent the extremity of October that were up of statement expectations. TMO reported pharma clients are feeling much assured navigating the dynamic US argumentation situation and are readying U.S. capableness expansions with beardown pipelines that TMO volition payment from via instrumentality income and their CDMO web successful coming years. The institution expects maturation to physique successful 2026 arsenic headwinds abate, exiting the twelvemonth astatine a tally complaint inline with its agelong word integrated gross maturation people of 3-6%."

Read Entire Article